Valneva Appoints MVM Partner Thomas Casdagli to its Supervisory Board
12 Dicembre 2019 - 10:45PM
Saint-Herblain (France), December 12,
2019 – Valneva SE (“Valneva” or “the Company”) today
announced the appointment of MVM Partner Thomas Casdagli to its
Supervisory Board. Mr. Casdagli is replacing Dr. Bali Muralidhar as
MVM Partners LLP representative.
Based in the UK and the US, leading healthcare
investor MVM Partners is one of Valneva’s largest shareholders. MVM
acquired 7.5% of Valneva’s ordinary share capital in 2016 and has
subsequently increased its stake to 8.7%.
Thomas Casdagli joined MVM Partners in 2002 and
has 17 years experience in investing in innovative life science
companies. Before joining MVM, he qualified as a chartered
accountant with PricewaterhouseCoopers’ Private Equity and Venture
Capital practice. Thomas Casdagli has an MBioch in Molecular and
Cellular Biochemistry from Oxford University and is currently a
member of the boards of eZono AG, Onbone Oy and Patient Connect
Ltd.
Thomas Lingelbach, Chief Executive
Officer of Valneva, commented, “We would like to thank
Bali for his dedication during the past three years and wish him
well in his future endeavors. We are delighted to welcome Thomas on
our board and are very much looking forward to working with
him.”
“With the continued strong performance of the
company’s commercial vaccines and important data from the Lyme and
chikungunya programs expected soon, it is a very exciting time to
be joining the Valneva board and I look forward to working with the
team”, MVM Partner Thomas Casdagli added.
About Valneva SE
Valneva is a biotech company developing and
commercializing vaccines for infectious diseases with major unmet
needs. Valneva’s portfolio includes two commercial vaccines for
travelers: IXIARO®/JESPECT® indicated for the prevention of
Japanese encephalitis and DUKORAL® indicated for the prevention of
cholera and, in some countries, prevention of diarrhea caused by
ETEC. The Company has various clinical-stage vaccines in
development including unique vaccines against Lyme disease and
chikungunya. Valneva has operations in Austria, Sweden, the United
Kingdom, France, Canada and the US with approximately 490
employees. More information is available at www.valneva.com.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineGlobal Head of Investor Relations & Corporate
CommunicationsM +33 (0)6 4516 7099investors@valneva.com |
Teresa
PinzolitsCorporate Communications SpecialistT +43 (0)1 20620
1116communications@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2019_12_12_VLA_SB_Appointment_PR_EN_Final
Grafico Azioni Valneva (EU:VLA)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Valneva (EU:VLA)
Storico
Da Mar 2023 a Mar 2024